Clinical Proof
The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy, Free Radical Biology and Medicine (2006)
The results of a peer-reviewed study (Free Radical Biology and Medicine, 2006) showed Protandim eliminates the age-related increase in cell aging factors.
In the clinical trials, blood samples from men and women, young and old, consistently demonstrated that after 30 days, taking one caplet a day, test subjects realized a 40 percent average decrease in TBARS—the progressive aging rate of a 20 year old.
When maintained for 120 days, Protandim significantly increased activity of SOD and CAT antioxidant enzymes by 54 percent, substantially increasing the body’s antioxidant defenses.*
Click here to view the study.
Normal subjects before supplementation with Protandim showed an age-dependent increase in TBARS (blue circles). The levels of TBARS dropped an average of 40% (p<0.0001) after 30 days of Protandim supplementation (green circles), and the age-related increase in TBARS virtually disappeared. This effect (gray circles) was maintained at 120 days with continued Protandim use.
Protandim® Found to Prevent a Process that Causes Blood Vessel Blockage in New Peer-Reviewed Study From The Ohio State University
Protandim prevents the proliferation of cells that can cause re-blockage of vessels following coronary artery bypass surgery, stenting, and carotid enarterectomy
A new peer-reviewed study involving Protandim, sponsored by the American Heart Association and the National Institutes of Health, was published in the scientific journal Free Radical Biology and Medicine. The study, conducted by researchers at The Ohio State University, examined the biochemical mechanisms that underlie the ability of Protandim to suppress intimal hyperplasia (over-proliferation of cells that line the vessel wall), a common adverse event that limits the effectiveness of several types of vascular surgery. Protandim has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates Protandim's ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes", which include most of the antioxidant enzymes.
The study, titled "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway" by Binata Joddar, Rashmeet K. Reen, Michael S. Firstenberg, Saradhadevi Varadharaj, Joe M. McCord, Jay L. Zweier, and Keith J. Gooch is published in the journal Free Radical Biology and Medicine . .
Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study
Protandim's ability to modulate relationship between superoxide dismutase and tumor suppressor p53 believed responsible for reduction of skin cancers in mice
A study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer. Protandim®, a patented dietary supplement comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates Protandim's® ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes", specifically in regard to chemoprevention.
New Peer Reviewed Study Concludes That Protandim® Improves Markers of Oxidative Stress and Fibrosis in Muscular Dystrophy Mice
The study, titled The Dietary Supplement Protandim® Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice by M.M. Qureshi, W.C. McClure, N.L. Arevalo, R.E. Rabon, B. Mohr, S.K. Bose, J.M. McCord, and B.S. Tseng, documents a 48% decrease in plasma TBARS, a marker of lipid peroxidation and oxidative stress, a 57% decrease in plasma osteopontin, a fibrosis-promoting factor linked to heart failure, and a 35% increase in beneficial, protective plasma PON1 activity in those mice given Protandim® compared to those without Protandim. PON1 is an enzyme thought to protect against atherosclerosis by preventing the oxidation of low-density lipoprotein (LDL) cholesterol.
Prestigious American Heart Association Journal, Circulation, Publishes New Peer-Reviewed Study Involving Protandim®
Dr. Norbert Voelkel and researchers at Virginia Commonwealth University (VCU), demonstrated the ability of Protandim, the Company’s patented dietary supplement composed of five highly synergistic “indirect antioxidants”, to protect the heart in a laboratory model of pulmonary hypertension in rats. “We are encouraged by the results of this study, which was independently funded and independently conducted by Dr. Voelkel and his colleagues at VCU,” stated David Brown, President & CEO of LifeVantage.
“These results illustrate the unique antioxidant, anti-inflammatory, and anti-fibrotic properties of Protandim. Scientists have long known of the involvement of oxidative stress in disease processes, and this study is a significant example of how oxidative stress affects susceptibility to right heart failure in animals. Although it would be premature to conclude that similar benefits would be seen in humans, these remarkable results open the door to the possibility of future research on pulmonary hypertension and Protandim in humans.”
.
Synergistic induction of heme oxygenase-1 by the components of an antioxidant supplement Protandim, Free Radical Biology and Medicine (2008)
Results of a new peer-reviewed study (Free Radical Biology & Medicine, on November 18, 2008) clearly demonstrate that Protandim produces a 300 percent increase in glutathione, which is a key antioxidant and anti-aging factor. In addition, the study shows that Protandim’s synergistic formulation provides more antioxidant power than any food or conventional supplement.
2009 Peer Reviewed Study from Louisiana State, PLoS ONE Journal.
Peer Reviewed Study from Louisiana State University, "Protandim®, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model," Published in PLoS ONE Journal.
PROTANDIM HAS BEEN ISSUED THREE PATENTS AND HAS BEEN FEATURED ON ABC's PRIMETIME.
Protandim has been studied by numerous universities in their own funded trials because scientists who know about the true science of oxidative stress are so excited about the potential. These universities include:
University of Colorado
Denver Health Medical Center
Children's Hospital, Denver
Virginia Commonwealth University
Colorado State University
University of Florida
University of Kentucky
University of Michigan
Louisiana State University
Ohio State University
Vanderbilt University
Glamorgan University, Wales
Sahlgrenska University Hospital, Goteborg, Sweden
University Hospital, Brno, Czech Republic
Mexican Institute of Social Security, Mexico City
